Clinical Trial Update: An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) [Phase 1]

View source ↗

Summary

This completed Phase 1 open-label study assessed whether CYP3A4 induction alters the pharmacokinetics of bortezomib (Velcade) in patients with multiple myeloma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• Velcade (bortezomib) (bortezomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Multiple Myeloma, Non-Hodgkin's Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2011-07-13